ArticleTherapeutic advances in medical oncology2025

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring

Masashi Ishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.